For the discovery of drugs that inhibit macrophage activation for use in severe cases of COVID-19. These drugs may suppress cytokine storm, hyperinflammation, and pulmonary infiltration to prevent respiratory failure.
- Funded by Emergent Ventures Fast Grants
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
Emergent Ventures Fast GrantsPrincipal Investigator
Dr. Kipp WeiskopfResearch Location
United States of AmericaLead Research Institution
Whitehead Institute for Biomedical ResearchResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
N/ASpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable